S&P 500   3,858.00 (+0.07%)
DOW   31,004.41 (+0.14%)
QQQ   329.11 (+0.30%)
AAPL   143.05 (+0.09%)
MSFT   233.37 (+1.67%)
FB   283.06 (+1.82%)
GOOGL   1,913.47 (+1.01%)
AMZN   3,331.46 (+1.14%)
TSLA   889.82 (+1.02%)
NVDA   538.90 (-1.32%)
BABA   263.63 (+0.86%)
CGC   35.32 (+7.32%)
GE   11.50 (+4.64%)
MU   80.64 (-0.79%)
AMD   95.20 (+1.14%)
NIO   59.48 (-0.85%)
T   29.55 (+1.51%)
F   11.18 (-0.97%)
ACB   10.69 (+5.22%)
BA   202.90 (-0.23%)
DIS   170.10 (-1.04%)
NFLX   561.85 (+0.91%)
GILD   66.70 (-2.14%)
S&P 500   3,858.00 (+0.07%)
DOW   31,004.41 (+0.14%)
QQQ   329.11 (+0.30%)
AAPL   143.05 (+0.09%)
MSFT   233.37 (+1.67%)
FB   283.06 (+1.82%)
GOOGL   1,913.47 (+1.01%)
AMZN   3,331.46 (+1.14%)
TSLA   889.82 (+1.02%)
NVDA   538.90 (-1.32%)
BABA   263.63 (+0.86%)
CGC   35.32 (+7.32%)
GE   11.50 (+4.64%)
MU   80.64 (-0.79%)
AMD   95.20 (+1.14%)
NIO   59.48 (-0.85%)
T   29.55 (+1.51%)
F   11.18 (-0.97%)
ACB   10.69 (+5.22%)
BA   202.90 (-0.23%)
DIS   170.10 (-1.04%)
NFLX   561.85 (+0.91%)
GILD   66.70 (-2.14%)
S&P 500   3,858.00 (+0.07%)
DOW   31,004.41 (+0.14%)
QQQ   329.11 (+0.30%)
AAPL   143.05 (+0.09%)
MSFT   233.37 (+1.67%)
FB   283.06 (+1.82%)
GOOGL   1,913.47 (+1.01%)
AMZN   3,331.46 (+1.14%)
TSLA   889.82 (+1.02%)
NVDA   538.90 (-1.32%)
BABA   263.63 (+0.86%)
CGC   35.32 (+7.32%)
GE   11.50 (+4.64%)
MU   80.64 (-0.79%)
AMD   95.20 (+1.14%)
NIO   59.48 (-0.85%)
T   29.55 (+1.51%)
F   11.18 (-0.97%)
ACB   10.69 (+5.22%)
BA   202.90 (-0.23%)
DIS   170.10 (-1.04%)
NFLX   561.85 (+0.91%)
GILD   66.70 (-2.14%)
S&P 500   3,858.00 (+0.07%)
DOW   31,004.41 (+0.14%)
QQQ   329.11 (+0.30%)
AAPL   143.05 (+0.09%)
MSFT   233.37 (+1.67%)
FB   283.06 (+1.82%)
GOOGL   1,913.47 (+1.01%)
AMZN   3,331.46 (+1.14%)
TSLA   889.82 (+1.02%)
NVDA   538.90 (-1.32%)
BABA   263.63 (+0.86%)
CGC   35.32 (+7.32%)
GE   11.50 (+4.64%)
MU   80.64 (-0.79%)
AMD   95.20 (+1.14%)
NIO   59.48 (-0.85%)
T   29.55 (+1.51%)
F   11.18 (-0.97%)
ACB   10.69 (+5.22%)
BA   202.90 (-0.23%)
DIS   170.10 (-1.04%)
NFLX   561.85 (+0.91%)
GILD   66.70 (-2.14%)
Log in
NASDAQ:NEPH

Nephros Stock Forecast, Price & News

$7.91
+0.11 (+1.41 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.18
Now: $7.91▼
$7.91
50-Day Range
$7.66
MA: $8.05▼
$8.58
52-Week Range
$4.42
Now: $7.91▼
$10.00
Volume12,725 shs
Average Volume12,815 shs
Market Capitalization$78.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.88
Nephros, Inc., a commercial-stage company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to health care, food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.

MarketRank™

Overall MarketRank™

2.16 out of 5 stars

Medical Sector

867th out of 1,922 stocks

Surgical & Medical Instruments Industry

84th out of 168 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEPH
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.nephros.com
Phone201 343 5202
Employees25
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.05
Current Ratio4.94
Quick Ratio2.68

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.33 million
Price / Sales7.55
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.95 per share
Price / Book8.33

Profitability

EPS (Most Recent Fiscal Year)($0.45)
Net Income$-3,420,000.00
Net Margins-43.58%
Return on Equity-36.33%
Return on Assets-26.47%

Miscellaneous

Outstanding Shares9,865,000
Market Cap$78.03 million
Next Earnings Date2/25/2021 (Estimated)
OptionableNot Optionable
$7.91
+0.11 (+1.41 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NEPH News and Ratings via Email

Sign-up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nephros (NASDAQ:NEPH) Frequently Asked Questions

How has Nephros' stock been impacted by COVID-19 (Coronavirus)?

Nephros' stock was trading at $7.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NEPH shares have increased by 5.9% and is now trading at $7.91.
View which stocks have been most impacted by COVID-19.

Is Nephros a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Nephros stock.
View analyst ratings for Nephros or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Nephros?

Wall Street analysts have given Nephros a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nephros wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Nephros' next earnings date?

Nephros is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Nephros.

How were Nephros' earnings last quarter?

Nephros, Inc. (NASDAQ:NEPH) released its quarterly earnings results on Thursday, November, 5th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.04. The company earned $2.12 million during the quarter. Nephros had a negative net margin of 43.58% and a negative trailing twelve-month return on equity of 36.33%.
View Nephros' earnings history.

What guidance has Nephros issued on next quarter's earnings?

Nephros updated its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.31 million.

What price target have analysts set for NEPH?

2 analysts have issued 1 year price objectives for Nephros' shares. Their forecasts range from $12.50 to $16.00. On average, they expect Nephros' stock price to reach $14.25 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price.
View analysts' price targets for Nephros or view Wall Street analyst' top-rated stocks.

Are investors shorting Nephros?

Nephros saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 11,100 shares, an increase of 26.1% from the December 15th total of 8,800 shares. Based on an average trading volume of 15,100 shares, the days-to-cover ratio is presently 0.7 days.
View Nephros' Short Interest.

Who are some of Nephros' key competitors?

Some companies that are related to Nephros include The Westaim (WEDXF), IRadimed (IRMD), RenovaCare (RCAR), Titan Medical (TMDI), Soliton (SOLY), Repro Med Systems (KRMD), Repro-Med Systems (REPR), TELA Bio (TELA), Isoray (ISR), DarioHealth (DRIO), PolyPid (PYPD), Avinger (AVGR), PAVmed (PAVM), Lyra Therapeutics (LYRA) and Liquidia (LQDA).
View all of NEPH's competitors.

Who are Nephros' key executives?

Nephros' management team includes the following people:
  • Mr. Andrew Astor, CEO, Pres, COO & Director (Age 64, Pay $355.61k)
  • Mr. Daniel S. D'Agostino, Chief Financial Officer (Age 54)
  • Ms. Joleen C. Turner, VP of Marketing & Bus. Devel.
  • Mr. Shane Sullivan, VP of Sales
  • Mr. Greg Lucas, Pres of Aether Water Systems

What is Nephros' stock symbol?

Nephros trades on the NASDAQ under the ticker symbol "NEPH."

How do I buy shares of Nephros?

Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nephros' stock price today?

One share of NEPH stock can currently be purchased for approximately $7.91.

How big of a company is Nephros?

Nephros has a market capitalization of $78.03 million and generates $10.33 million in revenue each year. The company earns $-3,420,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis. Nephros employs 25 workers across the globe.

What is Nephros' official website?

The official website for Nephros is www.nephros.com.

How can I contact Nephros?

Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201 343 5202.

This page was last updated on 1/26/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.